Results 1 to 10 of about 451,745 (342)

Development of fluorine-substituted NH₂-biphenyl-diarylpyrimidines as highly potent non-nucleoside reverse transcriptase inhibitors: Boosting the safety and metabolic stability. [PDF]

Acta Pharm Sin B, 2023
Jin X, Wang S, Zhao L, Huang W, Zhang Y, Pannecouque C, De Clercq E, Meng G, Piao H, Chen F.   +9 more
europepmc   +1 more source

Inhibition of telomerase activity by human immunodeficiency virus (HIV) nucleos(t)ide reverse transcriptase inhibitors: a potential factor contributing to HIV-associated accelerated aging.

Journal of Infectious Diseases, 2013
E. Leeansyah, P. Cameron, A. Solomon, S. Tennakoon, P. Velayudham, M. Gouillou, T. Spelman, A. Hearps, C. Fairley, D. Smit, A. Pierce, Jude Armishaw, S. Crowe, D. Cooper, K. Koelsch, Jun-Ping Liu, J. Chuah, S. Lewin   +17 more
semanticscholar   +1 more source

Liver Damage During Treatment with Reverse-Transcriptase Inhibitors in HIV Patients. [PDF]

Curr Health Sci J
Lungu GN, Diaconescu GI, Dumitrescu F, Docea OO, Mitrut R, Giubelan L, Zlatian O, Mitrut P.   +7 more
europepmc   +1 more source

High prevalence of reverse transcriptase inhibitors associated resistance mutations among people living with HIV on dolutegravir-based antiretroviral therapy in Francistown, Botswana. [PDF]

J Antimicrob Chemother
Choga OT, Lemogang GM, Choga WT, Muzanywa G, Shadreck TM, Ralegoreng C, Maruapula D, Moraka NO, Koofhethile CK, Mokgethi PT, Seru K, Zuze BJL, Montshosi P, Gobe I, Motswaledi MS, Musonda R, Mbulawa MB, Makhema J, Shapiro R, Lockman S, Chebani T, Nawa J, Bochena L, Moyo S, Gaseitsiwe S.   +24 more
europepmc   +1 more source

No accelerated progression of subclinical atherosclerosis with integrase strand transfer inhibitors compared to non-nucleoside reverse transcriptase inhibitors. [PDF]

J Antimicrob Chemother
García-Abellán J, García JA, Padilla S, Fernández-González M, Agulló V, Mascarell P, Botella Á, Gutiérrez F, Masiá M.   +8 more
europepmc   +1 more source

Clinical benefits of novel non-nucleoside reverse transcriptase inhibitors: A prospective cohort study. [PDF]

Immun Inflamm Dis
Ma S, Xie X, Fu Y, Gan L, Yang X, Kong L, Li J, Long H.   +7 more
europepmc   +1 more source

Nucleoside Reverse Transcriptase Inhibitors Are the Major Class of HIV Antiretroviral Therapeutics That Induce Neuropathic Pain in Mice. [PDF]

Int J Mol Sci
Bush K, Wairkar Y, Tang SJ.
europepmc   +1 more source

Association between the CYP2B6 polymorphisms and nonnucleoside reverse transcriptase inhibitors drug-induced liver injury: a systematic review and meta-analysis. [PDF]

Sci Rep
Chanhom N, Sonjan J, Inchai J, Udomsinprasert W, Chaikledkaew U, Suvichapanich S, Mahasirimongkol S, Jittikoon J.   +7 more
europepmc   +1 more source

Effect of Mutations at Position E138 in HIV-1 Reverse Transcriptase and Their Interactions with the M184I Mutation on Defining Patterns of Resistance to Nonnucleoside Reverse Transcriptase Inhibitors Rilpivirine and Etravirine

Antimicrobial Agents and Chemotherapy, 2013
Hong-tao Xu, S. Colby-Germinario, Eugene Asahchop, Maureen Oliveira, M. McCallum, Susan M. Schader, Yingshan Han, Y. Quan, S. Sarafianos, M. Wainberg   +9 more
semanticscholar   +1 more source

Bioisosterism-driven design of orally active, safe, and broad-spectrum biphenyl-DAPY derivatives as highly potent HIV-1 non-nucleoside reverse transcriptase inhibitors. [PDF]

Acta Pharm Sin B
Chen XM, Hao QQ, Pannecouque C, De Clercq E, Wang S, Chen FE.   +5 more
europepmc   +1 more source